Krystal Biotech (KRYS) Cash from Operations (2016 - 2026)

Krystal Biotech has disclosed Cash from Operations across 11 years of filings, most recently posting 80382000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 80382000.0, up 159.56% year-over-year; the trailing twelve-month figure through Mar 2026 was 250278000.0 (up 80.7% YoY), and the FY2025 annual result was 200865000.0, up 62.75% from the prior year.
• Cash from Operations came in at 80382000.0 for Q1 2026 at Krystal Biotech, up from 77508000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 80382000.0 in Q1 2026 to a low of 43059000.0 in Q2 2022.
• The 5-year median for Cash from Operations is 4168000.0 (2024), against an average of 12664352.94.
• Across the five-year window, Cash from Operations tumbled 325.11% in 2022 and surged 1365.09% in 2025, its largest moves.
• Krystal Biotech's Cash from Operations stood at 22329000.0 in 2022, then surged by 67.61% to 7232000.0 in 2023, then surged by 830.68% to 52843000.0 in 2024, then soared by 46.68% to 77508000.0 in 2025, then advanced by 3.71% to 80382000.0 in 2026.
• The last three Cash from Operations figures came in at 80382000.0 (Q1 2026), 77508000.0 (Q4 2025), and 39659000.0 (Q3 2025), per Business Quant data.